Stocks Worth Watching and Those to Ignore
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Yahoo Finance
- Genesco Sales Weakness: Genesco (NYSE:GCO) has experienced disappointing same-store sales over the past two years, indicating poor customer response to its product selection and in-store experience, leading to a stock price of $39.05 and a low price-to-sales ratio of 0.2, reflecting market concerns about its growth prospects.
- High Debt Risk: With a net debt-to-EBITDA ratio of 8x, Genesco may be forced to raise capital under unfavorable terms if market conditions deteriorate, further weakening its financial stability and investor confidence in the long term.
- XPO's Lackluster Growth: XPO (NYSE:XPO) has shown only 2.8% annual growth over the past two years, below industry averages, and its low gross margin of 19.8% reflects competitive pressures and high production costs, limiting profitability and shareholder returns.
- Restricted Free Cash Flow: XPO's free cash flow margin of just 1.6% restricts its ability to invest or reward shareholders with increased buybacks or dividends, leading to diminished investor confidence in its future performance, with a stock price of $216.44 and a forward P/E ratio of 44.8.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELV
Wall Street analysts forecast ELV stock price to fall
15 Analyst Rating
11 Buy
4 Hold
0 Sell
Moderate Buy
Current: 424.430
Low
332.00
Averages
389.07
High
425.00
Current: 424.430
Low
332.00
Averages
389.07
High
425.00
About ELV
Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to its Individual, Employer Group risk-based, Employer Group fee-based, BlueCard, Medicare, Medicaid and Federal Employee Program (FEP) members. The Health Benefits segment also offers health products on a full-risk basis. The CarelonRx segment includes its pharmacy services business. CarelonRx markets and offers pharmacy services to its affiliated health plan customers, as well as to external customers outside of the health plans. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services by offering an array of healthcare-related services and capabilities to internal and external customers through its Carelon Health and Carelon Insights businesses.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Stocks Worth Watching and Those to Ignore
- Genesco Sales Weakness: Genesco (NYSE:GCO) has experienced disappointing same-store sales over the past two years, indicating poor customer response to its product selection and in-store experience, leading to a stock price of $39.05 and a low price-to-sales ratio of 0.2, reflecting market concerns about its growth prospects.
- High Debt Risk: With a net debt-to-EBITDA ratio of 8x, Genesco may be forced to raise capital under unfavorable terms if market conditions deteriorate, further weakening its financial stability and investor confidence in the long term.
- XPO's Lackluster Growth: XPO (NYSE:XPO) has shown only 2.8% annual growth over the past two years, below industry averages, and its low gross margin of 19.8% reflects competitive pressures and high production costs, limiting profitability and shareholder returns.
- Restricted Free Cash Flow: XPO's free cash flow margin of just 1.6% restricts its ability to invest or reward shareholders with increased buybacks or dividends, leading to diminished investor confidence in its future performance, with a stock price of $216.44 and a forward P/E ratio of 44.8.
See More
US Stocks Close Mixed: Dow Hits All-Time High
- Dow Hits Record High: The Dow Jones Industrial Average rose 1.73% to reach an all-time high, reflecting strong rebounds in bank and managed healthcare stocks, despite a 0.53% decline in the Nasdaq 100 due to weakness in technology stocks.
- Crude Oil Prices Decline: WTI crude oil prices fell over 3%, lowering inflation expectations and pushing the 10-year T-note yield down 2 basis points to 4.47%, providing support for both stock and bond markets, indicating a complex market reaction to economic outlooks.
- Jobless Claims Rise: Initial jobless claims in the US increased by 13,000 to 225,000, marking a 3.75-month high, suggesting a weaker labor market, although unit labor costs were unexpectedly revised down to 1.8%, easing concerns over wage pressures.
- Earnings Season Summary: As of Thursday, 83% of the 494 S&P 500 companies reported earnings that beat estimates, with Q1 earnings projected to rise 12% year-over-year, but excluding the tech sector, growth is only about 3%, the lowest in two years, reflecting divergence across industries.
See More
Dow Jones Hits All-Time High Amid Mixed Market Performance
- Dow Jones High: The Dow Jones Industrial Average surged 1.49% to reach a new all-time high, demonstrating market resilience driven by strong performance in managed healthcare stocks, despite overall market pressures.
- Tech Sector Decline: Broadcom's stock plummeted over 14% due to disappointing AI revenue forecasts, leading to a broader decline in chipmakers, while CrowdStrike fell more than 8% despite beating Q1 earnings expectations, reflecting market caution towards tech stocks.
- Mixed Economic Data: Initial jobless claims rose to 225,000, a 3.75-month high, indicating a weaker labor market, while Q1 nonfarm productivity was revised down to 0.3%, below expectations, potentially impacting future economic growth outlooks.
- Oil Price Impact: WTI crude oil prices fell over 3% amid a ceasefire agreement between Israel and Lebanon, which lowered inflation expectations and provided support for both stock and bond markets, improving investor sentiment.
See More
Mixed US Stock Market with Tech Stocks Under Pressure
- Tech Stock Decline: Broadcom (AVGO) shares plummeted over 15% after its AI revenue forecast fell short, marking it as the largest decliner in the Nasdaq 100, which reflects growing concerns about the tech sector and may dampen investor confidence.
- Weak Employment Data: Initial jobless claims in the US rose by 13,000 to 225,000, reaching a 3.75-month high, indicating a weakening labor market that could lead to downward revisions in growth expectations.
- Healthcare Stocks Strong: UnitedHealth Group (UNH) surged over 6%, leading gains in the S&P 500, after Bank of America upgraded its rating from neutral to buy with a price target of $450, showcasing resilience in the healthcare sector.
- International Market Volatility: European markets showed mixed results, with Eurozone April retail sales falling 0.4% month-over-month, worse than the expected 0.3%, indicating weak consumer spending that could pressure future economic growth.
See More
Elevance Health Shares Rise as CMS Delays Sanctions
- Stock Price Recovery: Elevance Health (ELV) shares rose on Friday as the Centers for Medicare & Medicaid Services (CMS) decided to delay sanctions on its Medicare Advantage prescription drug plans, reflecting market recognition of the company's compliance efforts.
- Sanction Delay: In a letter to Elevance's Medicare Programs president Aimee Dailey, CMS stated that it would not impose intermediate sanctions at this time, considering the actions the company has recently taken, which buys the company valuable time to address compliance issues.
- Compliance Requirements: Despite the delay, CMS still requires Elevance to resolve the rejections identified in the risk adjustment processing system by June 30; otherwise, intermediate sanctions will take effect on July 1, increasing future compliance pressure on the company.
- Earnings Outlook: Following a strong Q1 performance, Elevance Health raised its 2026 adjusted EPS outlook to at least $26.75 while targeting at least 12% EPS growth in 2027, indicating positive progress in cost control efforts.
See More
US Stocks Close Higher: S&P 500 Hits All-Time High
- Market Performance: The S&P 500 rose by 0.61% and the Nasdaq 100 increased by 1.76%, reaching all-time highs, indicating strong demand for tech stocks amid falling oil prices and progress in US-Iran peace talks.
- Oil Price Volatility: WTI crude oil prices fell to a 2.5-week low as US-Iran negotiations aimed at reopening the Strait of Hormuz progressed, although military actions by US Central Command pressured market sentiment, leading to declines in energy stocks.
- Economic Data Impact: The Chicago Fed National Activity Index rose to a 13-month high of 0.14, surpassing expectations, while a slight decline in the consumer confidence index reflects the complexities of economic recovery, potentially influencing future market trends.
- Earnings Reports: As of Tuesday, 83% of the 475 S&P 500 companies reported earnings above expectations, with Q1 earnings projected to grow by 12% year-on-year, although excluding the tech sector, the increase is only 3%, highlighting disparities across industries.
See More
Stocks Worth Watching and Those to Ignore
- Genesco Sales Weakness: Genesco (NYSE:GCO) has experienced disappointing same-store sales over the past two years, indicating poor customer response to its product selection and in-store experience, leading to a stock price of $39.05 and a low price-to-sales ratio of 0.2, reflecting market concerns about its growth prospects.
- High Debt Risk: With a net debt-to-EBITDA ratio of 8x, Genesco may be forced to raise capital under unfavorable terms if market conditions deteriorate, further weakening its financial stability and investor confidence in the long term.
- XPO's Lackluster Growth: XPO (NYSE:XPO) has shown only 2.8% annual growth over the past two years, below industry averages, and its low gross margin of 19.8% reflects competitive pressures and high production costs, limiting profitability and shareholder returns.
- Restricted Free Cash Flow: XPO's free cash flow margin of just 1.6% restricts its ability to invest or reward shareholders with increased buybacks or dividends, leading to diminished investor confidence in its future performance, with a stock price of $216.44 and a forward P/E ratio of 44.8.
See More
US Stocks Close Mixed: Dow Hits All-Time High
- Dow Hits Record High: The Dow Jones Industrial Average rose 1.73% to reach an all-time high, reflecting strong rebounds in bank and managed healthcare stocks, despite a 0.53% decline in the Nasdaq 100 due to weakness in technology stocks.
- Crude Oil Prices Decline: WTI crude oil prices fell over 3%, lowering inflation expectations and pushing the 10-year T-note yield down 2 basis points to 4.47%, providing support for both stock and bond markets, indicating a complex market reaction to economic outlooks.
- Jobless Claims Rise: Initial jobless claims in the US increased by 13,000 to 225,000, marking a 3.75-month high, suggesting a weaker labor market, although unit labor costs were unexpectedly revised down to 1.8%, easing concerns over wage pressures.
- Earnings Season Summary: As of Thursday, 83% of the 494 S&P 500 companies reported earnings that beat estimates, with Q1 earnings projected to rise 12% year-over-year, but excluding the tech sector, growth is only about 3%, the lowest in two years, reflecting divergence across industries.
See More
Dow Jones Hits All-Time High Amid Mixed Market Performance
- Dow Jones High: The Dow Jones Industrial Average surged 1.49% to reach a new all-time high, demonstrating market resilience driven by strong performance in managed healthcare stocks, despite overall market pressures.
- Tech Sector Decline: Broadcom's stock plummeted over 14% due to disappointing AI revenue forecasts, leading to a broader decline in chipmakers, while CrowdStrike fell more than 8% despite beating Q1 earnings expectations, reflecting market caution towards tech stocks.
- Mixed Economic Data: Initial jobless claims rose to 225,000, a 3.75-month high, indicating a weaker labor market, while Q1 nonfarm productivity was revised down to 0.3%, below expectations, potentially impacting future economic growth outlooks.
- Oil Price Impact: WTI crude oil prices fell over 3% amid a ceasefire agreement between Israel and Lebanon, which lowered inflation expectations and provided support for both stock and bond markets, improving investor sentiment.
See More
Mixed US Stock Market with Tech Stocks Under Pressure
- Tech Stock Decline: Broadcom (AVGO) shares plummeted over 15% after its AI revenue forecast fell short, marking it as the largest decliner in the Nasdaq 100, which reflects growing concerns about the tech sector and may dampen investor confidence.
- Weak Employment Data: Initial jobless claims in the US rose by 13,000 to 225,000, reaching a 3.75-month high, indicating a weakening labor market that could lead to downward revisions in growth expectations.
- Healthcare Stocks Strong: UnitedHealth Group (UNH) surged over 6%, leading gains in the S&P 500, after Bank of America upgraded its rating from neutral to buy with a price target of $450, showcasing resilience in the healthcare sector.
- International Market Volatility: European markets showed mixed results, with Eurozone April retail sales falling 0.4% month-over-month, worse than the expected 0.3%, indicating weak consumer spending that could pressure future economic growth.
See More
Elevance Health Shares Rise as CMS Delays Sanctions
- Stock Price Recovery: Elevance Health (ELV) shares rose on Friday as the Centers for Medicare & Medicaid Services (CMS) decided to delay sanctions on its Medicare Advantage prescription drug plans, reflecting market recognition of the company's compliance efforts.
- Sanction Delay: In a letter to Elevance's Medicare Programs president Aimee Dailey, CMS stated that it would not impose intermediate sanctions at this time, considering the actions the company has recently taken, which buys the company valuable time to address compliance issues.
- Compliance Requirements: Despite the delay, CMS still requires Elevance to resolve the rejections identified in the risk adjustment processing system by June 30; otherwise, intermediate sanctions will take effect on July 1, increasing future compliance pressure on the company.
- Earnings Outlook: Following a strong Q1 performance, Elevance Health raised its 2026 adjusted EPS outlook to at least $26.75 while targeting at least 12% EPS growth in 2027, indicating positive progress in cost control efforts.
See More
US Stocks Close Higher: S&P 500 Hits All-Time High
- Market Performance: The S&P 500 rose by 0.61% and the Nasdaq 100 increased by 1.76%, reaching all-time highs, indicating strong demand for tech stocks amid falling oil prices and progress in US-Iran peace talks.
- Oil Price Volatility: WTI crude oil prices fell to a 2.5-week low as US-Iran negotiations aimed at reopening the Strait of Hormuz progressed, although military actions by US Central Command pressured market sentiment, leading to declines in energy stocks.
- Economic Data Impact: The Chicago Fed National Activity Index rose to a 13-month high of 0.14, surpassing expectations, while a slight decline in the consumer confidence index reflects the complexities of economic recovery, potentially influencing future market trends.
- Earnings Reports: As of Tuesday, 83% of the 475 S&P 500 companies reported earnings above expectations, with Q1 earnings projected to grow by 12% year-on-year, although excluding the tech sector, the increase is only 3%, highlighting disparities across industries.
See More
